Analysts Favor Eli Lilly Over Novo Nordisk Despite Stock Rally

Despite a 30 percent surge in Novo Nordisk's stock after significant losses, analysts are reportedly more confident in rival Eli Lilly for the coming years, even with Novo Nordisk's lead in the "pill war." The article reviews key figures explaining this skepticism.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

berlingskenob33d ago

Trods aktieoptur tror analytikerne mest på rival – centrale tal forklarer Novo-skepsis

Efter massive kurstæsk har investorerne sendt Novo Nordisk-aktien op med 30 procent. Trods et markant forspring i pillekrigen fæstner analytikerne dog størst lid til rivalen Eli Lilly det næste par år. Berlingske gennemgår en række centrale tal, der kan illustrere analytikernes skepsis.

Read full article →

PERSPECTA

PERSPECTA

Analysts Favor Eli Lilly Over Novo Nordisk Despite Stock Rally

Sources

Trods aktieoptur tror analytikerne mest på rival – centrale tal forklarer Novo-skepsis

Related Stories

Canadian Home Prices Rise in July as New Listings Slow

Pimco Executive Notes Wealth Firms' Retreat from Private Credit

Dangote Refinery Secures $1 Billion Backing for Planned IPO

Salmonella Outbreak Leads to Recall of 40,000 Eggs from Finnish Farm

PERSPECTA